Oral PI3K, BTK, Bcl-2 inhibitors are set to bring a change in treatment
paradigm of hematological malignancies (CLL, iNHL, ALL). Curis’s (CRIS) pipeline
consists of a marketed drug Erivedge (L in US, R in EU/other, vismodegib,
HedgeHog pathway inhibitor) and CUDC-907 (PI3K/HDAC dual inhibitor, PhI) in PhI
besides other products. BTK, PI3K and HDAC are clinically validated targets for
treating leukemia’s. Current SoC includes IV/SC mAbs (Rituxan/MabThera, Arzerra)
in combinations with chemotherapy. There remains an unmet need for pts who are
resistant or can not tolerate these treatment options.
There are not too many unpartnered PI3K inhibitors in the pipeline and early
promising data could trigger………. For more details, please read our report
released on 11th February. 2013 on CRIS titled “Time to Assess Value Beyond
Erivedge!
0 items in cart
